Regulations; section 56 refers to Institutional Review Boards [IRBs] 4 ). In addition, the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) has summarized recent international efforts to identify points of agreement among the FDA and other national authorities about regulations for medical research. Specifically, Section 5.5 of the ICH Good Clinical Practice Consolidated Guidelines 5 provides some guidance on the use of DSMCs in clinical studies. After stating that the sponsor of a trial should use "appropriately qualified" individuals to conduct the study, this section suggests that the sponsor should also consider establishing an "independent data monitoring committee" to assess the progress of the trial and make recommendations about whether it should be continued, modified, or stopped. The ICH document also specifies that the operating procedures for such a group should be put in a written form and that written records of all meetings should be maintained.
The National Institutes of Health
The National Cancer Institute (NCI) of the National Institutes of Health (NIH) recently published a policy document on "Data and Safety Monitoring of Clinical Trials." 6 The document states that phase I and phase II studies may be monitored by the principal investigator or NCI program staff but that phase III trials require a formal DSMC. According to the institute, DSMC members have many responsibilities, which include familiarizing themselves with the study protocol (input is not part of the charge), reviewing interim analyses and data relating to trial performance, recommending trial continuation or termination, and deciding to whom the study results should go before publication. Members are also responsible for reviewing reports of related studies, monitoring study operation to assist in resolving study operational weaknesses and problems, reviewing major proposed modifications of the protocol before its implementation, and providing written reports of meetings and proceedings. Investigators working on a study are specifically excluded from participating in DSMC discussions about outcome data. Decisions to alter the design of a trial or to stop it are left to "the trial principal investigator/project manager, DSMC Chair, and the NCI Division Director or designee," all of whom "will be responsible for reaching a mutually acceptable decision about the study." 3 ) Such information is crucial to DSMCs because the decisions that they make in particular trial circumstances may affect the decisions that regulators make about future medical research; furthermore, other entities may follow patient safety issues in parallel with a DSMC. In the United States the FDA has legal jurisdiction over any human experimentation that involves investigational products. It was the first government authority granted regulatory authority over medical products; in the last few decades, most other countries have established similar regulatory bodies with similar jurisdiction within their borders.
What regulations currently govern DSMCs?
